Wed, Aug 20, 2014, 6:45 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Sangamo Biosciences Inc. Message Board

  • gswkool gswkool Jul 16, 2012 4:33 PM Flag

    Alnylam

    Shares of Alnylam ALNY +53.04% today after it released positive results from a Phase I clinical study for its drug candidate ALN-TTR02. The company is testing the compound on patients with a genetic disease known as TTR-mediated amyloidosis, or ATTR. ALN-TTRO2 is part of a new class of gene-targeting drugs known as RNAi therapeutics.

    Alnylam rocked it on Phase I and the shares responded. They rocked it for a drug that treats I believe 200K patients and they have orphan drug designation.

    Can't imagine what will happen if positive news for HIV treatment comes out of SGMO. Even phase I news that shows a response.....

    Should get interesting over the next several months...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SGMO
13.65-0.49(-3.47%)Aug 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.